Biotech | September 08, 2021
Biocon settles suit with Celgene for generic Revlimid
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
It’s an AB-rated generic therapeutic version of Durezol
It had an estimated market size of US $ 32 million as of June 2021
Subscribe To Our Newsletter & Stay Updated
